Advancing the Apitox Development Program
Nexus Biosys operates under Apimeds Pharmaceuticals US, Inc. The company supports clinical development strategies, regulatory preparations, and program evaluation for Apitox in knee osteoarthritis.
Focused on Biopharmaceutical Development
Nexus Biosys is presented within the Apimeds Pharmaceuticals US corporate platform as a biopharmaceutical business focused on the Apitox development program.
Apimeds Pharmaceuticals US, Inc. is listed on NYSE American under the trading symbol APUS.
Important Corporate Clarification
Nexus Biosys is not separately listed on a stock exchange. References to NYSE American and the symbol APUS relate exclusively to Apimeds Pharmaceuticals US, Inc.
Clinical Development & Status
Apitox is the biopharmaceutical program associated with Nexus Biosys in the supplied APUS corporate presentation.
Lead Program
The presentation identifies Apitox as a development program for knee osteoarthritis and describes it as being in Phase III clinical development.
Development Status
Program: Apitox
Indication: Knee osteoarthritis
Status: Phase III clinical development program
Registry Compliance
Clinical development status, study initiation, recruitment and regulatory progress should be communicated only through formally approved company announcements and official clinical-trial records.
Assigned Contractual & Economic Rights
On August 19, 2026, Apimeds Pharmaceuticals US, Inc. entered into an Assignment and Transfer Agreement with FreeT Inc. covering certain Apitox-related rights held by FreeT.
Korean Medicine Clinics
100% of FreeT’s rights relating to the Apitox market for Korean medicine clinics in the Republic of Korea.
U.S. Commercial Royalties
A 25% royalty entitlement on defined economic proceeds arising from the development, licensing, sale or other commercialization of Apitox in the United States.
Overseas Net Proceeds
A 25% participation right in net proceeds from overseas rights agreements.
Important Attribution & Scope
These rights were assigned to Apimeds Pharmaceuticals US, Inc. The SEC filing does not state that the rights were assigned directly to Nexus Biosys. The assignment is limited to rights held by FreeT and legally assignable as of the effective date.
Apimeds Pharmaceuticals US, Inc.
Parent company corporate profile and investor communication channels.
Matawan, New Jersey 07747, USA